The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked CRA to evaluate the policies that host governments of middle-income countries use to encourage investment in innovative activities and the implications for future innovation. CRA consultants looked at eight countries and concluded that there are six key lessons that appear to be critical for success. Read more in the article here:
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...